Topline data were announced from a phase 3 trial evaluating AD109 (aroxybutynin 2.5mg/atomoxetine 75mg) in participants with obstructive sleep apnea.

Obstructive Sleep Apnea (OSA) remains a widespread yet under-treated condition, affecting millions globally. Traditional treatments such as CPAP therapy, w | Drug Discovery And Development ...

Tirzepatide is now approved for the treatment of obstructive sleep apnea, highlighting the drug class' potential in sleep ...

“REM sleep is when your brain does some of its most important cleanup and memory storage work,” said co-corresponding author ...

Sleep apnea may lead to weight gain by disrupting sleep, affecting hunger hormones, slowing metabolism, and more. Lifestyle ...

Apnimed’s star sleep apnea asset has hit the latest landmark on its march down victory road. | Apnimed’s star sleep apnea ...

With the FDA authorization in place, Incannex will initiate Phase 3 immediately following the completion of Phase 2, leveraging a shared protocol and U.S. based infrastructure to maximize efficiency ...

Apnimed has announced positive topline results from its pivotal Phase 3 SynAIRgy clinical trial evaluating the efficacy and safety of AD109 in adults living with mid, moderate and severe OSA and acros ...

Pollinosis — an allergic reaction to pollen — was independently linked to an increased likelihood of having obstructive sleep apnea-hypopnea syndrome (OSAHS), and this association was stable ...

OSA-related hypoxemia linked to increased frontoparietal cerebrovascular pathology, which is associated with reduced medial temporal lobe integrity.

Medical cannabis has improved sleep for Minnesotans who suffer from obstructive sleep apnea, according to a new study ...